Intermittent Claudication - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 51
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I531B0AD5DEEN
Leaflet:

Download PDF Leaflet

Intermittent Claudication - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Intermittent Claudication - Pipeline Review, H2 2016’, provides an overview of the Intermittent Claudication pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication
  • The report reviews pipeline therapeutics for Intermittent Claudication by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Intermittent Claudication therapeutics and enlists all their major and minor projects
  • The report assesses Intermittent Claudication therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Intermittent Claudication
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Intermittent Claudication Overview
Therapeutics Development
Pipeline Products for Intermittent Claudication - Overview
Intermittent Claudication - Therapeutics under Development by Companies
Intermittent Claudication - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Intermittent Claudication - Products under Development by Companies
Intermittent Claudication - Companies Involved in Therapeutics Development
ID Pharma Co., Ltd.
Kowa Company, Ltd.
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.
Intermittent Claudication - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALD-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Intermittent Claudication - Dormant Projects
Intermittent Claudication - Discontinued Products
Intermittent Claudication - Product Development Milestones
Featured News & Press Releases
May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study
Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells
Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study
Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells
Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research
Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study
Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication
Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134
Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134
Nov 10, 2011: Kowa Announces Efficacy And Safety Of K-134 For Treatment Of Intermittent Claudication In AHA 2011
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Intermittent Claudication, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Intermittent Claudication - Pipeline by ID Pharma Co., Ltd., H2 2016
Intermittent Claudication - Pipeline by Kowa Company, Ltd., H2 2016
Intermittent Claudication - Pipeline by Nuo Therapeutics, Inc., H2 2016
Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Intermittent Claudication - Dormant Projects, H2 2016
Intermittent Claudication - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Intermittent Claudication, H2 2016
Number of Products under Development by Companies, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Intermittent Claudication Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 81 pages
Critical Limb Ischemia - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 145 pages

Ask Your Question

Intermittent Claudication - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: